Clinical trials: ST-Segment Elevation Myocardial Infarction
STEMI - ST Elevation Myocardial Infarction
Effect of PPCI on Diastolic Function & Levels of Galactin-3 in Patients With STEMI
2D Echocardiography with color Doppler assessment: It will be done within 24 h after PPCI Peripheral blood samples were obtained within 48 hours after acute MI, and the serum will be frozen at -70°C until tested for Galactin-3…
- Trial name
- NCT05107076
- Testing
- 2D Echocardiography with color Doppler assessment & Galactin-3 level in blood
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Assiut University
Thromboembolism
OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction
This is a randomized, double blindcontrolled, parallel group, multi-center, multinational study of fondaparinux vs. control in patients with STEMI (ST segment myocardial infarction) randomized within 24 hours of the onset of…
- Trial name
- NCT00064428
- Testing
- fondaparinux - UFH not indicated, Control - UFH not indicated, Fondaparinux - UFH indicated
- Volunteers
- 12,092 people
- Sponsor
- GlaxoSmithKline
Stable Angina, Unstable Angina
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial
We had little experience in coronary intervention with recently introduced newer drug-eluting stent (DES) platforms, despite great anticipation, and optimal duration of dual antiplatelet therapy (DAPT) for these stent systems…
- Conditions
- Stable Angina, Unstable Angina, Non-ST Segment Elevation Myocardial Infarction
- Trial name
- HOST-IDEA (NCT02601157)
- Testing
- 3-months DAPT, 1-year DAPT
- Where
- 12 sites in South Korea
- Volunteers
- 2,173 people
- Sponsor
- Seoul National University Hospital
ST Elevation Myocardial Infarction
Field Implementation of the autoRIC Device in STEMI
This is a "before and after" observational study of a therapeutic strategy to treat patients with confirmed ST-segment myocardial infarction (STEMI) with remote ischemic conditioning (RIC) before undergoing primary percutaneous…
- Trial name
- FIRST (NCT03265067)
- Testing
- autoRIC
- Where
- 2 sites in Canada
- Volunteers
- 1,622 people
- Sponsor
- William Osler Health System
Myocardial Infarction, Outcome
Acute and Chronic Protective Effects of Peri-interventional Administration of Levosimendan in ST Elevation Myocardial Infarctions
In the proposed project the investigators want to assess whether the approach of the post-conditioning by Levosimendan in patients with acute STEMI is safe and reproducible, can be used with a positive influence on the outcomes…
- Trial name
- NCT03022877
- Testing
- Levosimendan
- Sponsor
- RWTH Aachen University
ST-elevation Myocardial Infarction
Cooling in Myocardial Infarction
The primary goal in the treatment of acute myocardial infarction is to reperfuse the ischemic myocardium to reduce infarct size.
- Trial name
- STATIM (NCT01777750)
- Testing
- EMCOOLS flex pad; Philips Innercool RTx
- Where
- Austria
- Volunteers
- 120 people
- Sponsor
- Medical University of Vienna
Myocardial Infarction, Acute, Artificial Intelligence
The ALERT-Pilot Study
the algorithm of artificial intelligent to diagnose myocardial infarction through prior surgery Electrocardiogram was established.
- Conditions
- Myocardial Infarction, Acute, Artificial Intelligence, ECG Pattern
- Trial name
- NCT03317691
- Testing
- electrocardiogram diagnosed by artificial intelligence
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Shanghai 10th People's Hospital
Coronary Artery Disease, Acute Coronary Syndrome
BIOSTEMI Extended Survival
The objective of the BIOSTEMI ES study is to assess the long-term clinical outcomes with the Orsiro ultrathin-strut biodegradable polymer sirolimus-eluting stent compared to the Xience thin-strut durable polymer…
- Trial name
- BIOSTEMI ES (NCT05484310)
- Where
- 10 sites in Switzerland
- Volunteers
- 1,300 people
- Sponsor
- University Hospital, Geneva
Acute Myocardial Infarction, STEMI
Multi-modality Imaging in Acute Myocardial Infarction
The goal of this study is to use three (3) different imaging techniques:Fractional Flow Reserve (FFR) allows precise measurement of blood flow in the arteries to the heart, and is more reliable than pictures alone to determine…
- Conditions
- Acute Myocardial Infarction, STEMI, Coronary Artery Disease, Atherosclerotic Plaque Disruption With Thrombosis of Artery
- Trial name
- MIAMI (NCT02926755)
- Testing
- Coronary Angiography
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Corewell Health East
Myocardial Infarction, Left Ventricular Systolic Dysfunction
Objective Systolic Function Recuperation Assessed by Echocardiography
The purpose of this study is to evaluate left ventricular systolic ejection fraction and anterior or apical akinesis 1 month and 3 months after a myocardial infarction treated with primary PCI to determine whether improvement at…
- Conditions
- Myocardial Infarction, Left Ventricular Systolic Dysfunction, Anterior Akinesis, Apical Akinesis
- Trial name
- ROSE (NCT01086124)
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- Paul Farand
Left Ventricular Thrombus, ST Segment Elevation Myocardial Infarction
Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI
The purpose of the study is to assess the safety and efficacy of rivaroxaban-based versus warfarin-based antithrombotic regimens on outcomes of patients with left ventricle thrombosis following acute ST elevation myocardial…
- Trial name
- REWARF-STEMI (NCT05705089)
- Testing
- Rivaroxaban 15 MG, Warfarin
- Where
- 2 sites in Iran
- Volunteers
- 50 people
- Sponsor
- Rajaie Cardiovascular Medical and Research Center
STEMI - ST Elevation Myocardial Infarction, Myocardial Dysfunction
Percutaneous Revascularization in Infarction With Late Presentation and Absence of Viability: Effects on Left Ventricular Remodeling and Contractility
The purpose of this study is to evaluate whether late recanalization in patients with ST elevation myocardial infarction (STEMI) without Viability on Cardiovascular Magnetic Resonance Image (MRI) can reduce the reverse remodeling…
- Conditions
- STEMI - ST Elevation Myocardial Infarction, Myocardial Dysfunction, Percutaneous Coronary Intervention
- Trial name
- NCT05160311
- Testing
- Optimized Medical Treatment (OMT), Drug Eluting Stent (DES) Coronary Angioplasty
- Where
- Brazil
- Volunteers
- 70 people
- Sponsor
- Instituto Dante Pazzanese de Cardiologia
Acute Coronary Syndrome
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Losmapimod is a new anti-inflammatory medication which potentially may benefit patients with Acute Coronary Syndrome, (ACS), a condition which includes heart attack.
- Trial name
- LATITUDE (NCT02145468)
- Testing
- Losmapimod 7.5 mg twice daily, Standard therapy
- Where
- 341 sites in United States, Argentina and 32 more
- Volunteers
- 3,503 people
- Sponsor
- GlaxoSmithKline
Acute Coronary Syndrome
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
The purpose of this study is to compare the safety of two different dose regimens of unfractionated heparin (UFH) during a percutaneous coronary intervention (PCI) procedure in patients with UA (unstable angina)/NSTEMI (non ST…
- Trial name
- FUTURA/OASIS 8 (NCT00790907)
- Testing
- fondaparinux background and standard dose UFH, Fondaparinux background and low dose heparin, Open label fondaparinux
- Where
- 203 sites in United States, Argentina and 16 more
- Volunteers
- 3,235 people
- Sponsor
- GlaxoSmithKline
Primary PCI, ST-elevation Myocardial Infarction (STEMI)
Impact of Pre-Hospital Heparin Loading in STEMI Patients for Primary PCI: The HELP-PCI-2 Trial
This randomized, multicenter, prospective trial will enroll 6,294 participants in approximately 80 centers. STEMI patients with onset time within 12 hours and scheduled for primary PCI will be randomly assigned to two groups in a…
- Trial name
- HELP-PCI-2 (NCT07361783)
- Testing
- Unfractionated heparin treatment
- Where
- China
- Volunteers
- 6,294 people
- Sponsor
- Chen Jing
Acute Coronary Syndromes
A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction
The purpose of this trial is to investigate the potential benefits/risks regarding pretreatment with prasugrel in non-ST-elevation myocardial infarction (NSTEMI) participants with elevated troponin scheduled for coronary…
- Trial name
- ACCOAST (NCT01015287)
- Testing
- Prasugrel
- Where
- 153 sites in Austria, Belgium and 17 more
- Volunteers
- 4,033 people
- Sponsor
- Eli Lilly and Company
Acute Myocardial Infarction
Daily Variability of Platelet Aggregation in Patients With Myocardial Infarction Treated With Prasugrel and Ticagrelor
The aim of this study is to compare circadian variability of antiplatelet effect of prasugrel and ticagrelor maintenance doses during the initial days after acute myocardial infarction.
- Trial name
- DRAGON (NCT03454841)
- Testing
- Prasugrel, Ticagrelor
- Where
- 2 sites in Poland
- Volunteers
- 73 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Myocardial Infarction
Safety of Early Discharge Following Low Risk Myocardial Infarction
Objectives: The primary objective of this study is to evaluate the safety of an early discharge strategy in patients with low risk ST-elevation myocardial infarction (STEMI), treated with primary percutaneous coronary…
- Trial name
- EDAMI (NCT01868256)
- Testing
- early discharge (<72 h), Conventional discharge
- Where
- Spain
- Volunteers
- 1,558 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Acute Myocardial Infarction (AMI)
Dexrazoxane to Protect Against Hemorrhagic STEMI
This Phase Ila trial evaluates whether the intravenous administration of Dexrazoxane can reduce permanent heart muscle damage in patients undergoing standard stent procedures (PCI) for a severe heart attack (STEMI).
- Trial name
- SHIELD-MI (NCT07502521)
- Testing
- Dexrazoxane, Normal Saline
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Rohan Dharmakumar
ST Segment Elevation Myocardial Infarction, Elective Percutaneous Coronary Intervention
Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI
Elective percutaneous coronary intervention (EPCI) is the common treatment of ST segment elevation myocardial infarction (STEMI).Slow flow / no-reflow phenomenon following EPCI in STEMI patients has been a serious and common…
- Trial name
- NOSLOWFLOW-Ⅱ (NCT03406832)
- Testing
- Nitroprusside Sodium, Tirofiban Hydrochloride, Heparinized saline
- Where
- 28 sites in China
- Volunteers
- 1,000 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University